{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Assessment of the treatment response was evaluated according to internationally recognized response criteria for multiple myeloma, non-Hodgkin's lymphoma, acute myeloid leukemia, chronic myeloid leukemia.\n\n\"Response\" was defined as at least partial response or partial remission (PR) according to the criteria for efficacy assessment.","groups":[{"description":"OPB-51602: 1, 2, 3, 4 and 6 mg/day oral once daily (QD) in a 4 week cycle\n\nOPB-51602: once daily during the treatment period","id":"OG000","title":"OPB-51602"}],"paramType":"NUMBER","populationDescription":"Efficacy population included all treated subjects who had received at least 1 dose of study drug.\n\nNo statistical analysis provided for treatment response.","reportingStatus":"POSTED","timeFrame":"From first dose of study medication to withdrawal examination","title":"Treatment Response","type":"SECONDARY","unitOfMeasure":"participants"}